Firsocostat (GS-0976) is a hepatic ACC1 and ACC2 inhibitor that reduces steatosis, inhibits DNL and reduces serum fibrosis markers in non-cirrhotic NASH patients in a Phase II trial (264). Here, ACACA is linked to metabolic dysfunction-associated steatohepatitis.